Brought to you by 
Reata Pharmaceuticals closes $22.6mm Series D round
16 Aug 2006
Executive Summary
Reata Pharmaceuticals (developing therapeutics to treat cancer and inflammatory and neurodegenerative diseases) has raised $22.6mm with the closing of its Series D venture round led by Cardinal Investment. New backers included Novo AS, which will now have a representative on the company's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Reata Pharmaceuticals closes $22.6mm Series D round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice